Dual agonism improves glycemic control, delays gastric emptying, reduces caloric intake, and enhances metabolic efficiency
No increased cardiovascular risk was observed with tirzepatide in T2D participants versus controls
Gorgojo-Martnez, J.J., et al
These devices depend on high C ratings for speed and performance
Wichmann A, Allahyar A, Greiner TU, Plovier H, Lunden GO, Larsson T, et al
Combination With Mineralocorticoid Receptor Antagonists and Endothelin Receptor Antagonists The nonsteroidal, selective mineralocorticoid receptor antagonist finerenone exhibits beneficial effects on reducing fibrosis and inflammation and was found in the FIDELIO-DKD trial to reduce albuminuria, CKD progression, and cardiovascular events in T2DM patients with eGFR 25 to 60 ml/min per 1.73 m 2 and UACR 30 to 300 mg/g or eGFR 25 to 75 ml/min per 1.73 m 2 and UACR 300 to 5000 mg/g